"The updated 4th edition (2016) to the WHO classification of CNS tumours required molecularly distinct populations of both components to be identified: astrocytic (IDH-mutant, ATRX-mutant, 1p19q-intact) and oligodendrocytic (IDH-mutant, ATRX-wildtype, 1p19q co-deleted) 8."
"The updated 4th edition (2016) to the WHO classification of CNS tumours required molecularly distinct populations of both components to be identified: astrocytic (IDH-mutant, ATRX-mutant, 1p19q-intact) and oligodendrocytic (IDH-mutant, ATRX-wildtype, 1p19q co-deleted) 8."